Neuland Laboratories : Unaudited Financial Results (Consolidated and Standalone) for Q3FY 2023
February 15, 2023 at 06:47 am EST
Share
�f
NEULAND
WHERE OPPORTIJNITY BECOMES R.IALITY
Neuland Laboratories Limited
11th Floor, (5th Office Level),
Phoenix IVY Building,
Plot No. 573A-III, Road No.82,
Jubilee Hills, Hyderabad-500033,
Telangana, India
February 13, 2023
Tel: 040 67611600 I 67611700
Email : neuland@neulandlabs.com
To
www.neulandlabs.com
BSE Limited
The National Stock Exchange of India Ltd
Phiroze Jeejeebhoy Towers, 25th Floor,
Exchange Plaza,
Dalal Street, Mumbai - 400 001
Sandra Kurla Complex
Sandra (E), Mumbai - 400 001
Scrip Code: 524558
Scrip Code: NEULANDLAB; Series: EQ
Dear Sir/Madam,
Sub: Outcome of Board Meeting - Un-audited Standalone & Consolidated Financial Results for the quarter and nine months ended December 31, 2022
Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at their meeting held on even date, i.e. February 13, 2023, has inter alia, approved the Unaudited Financial Results (standalone & consolidated) of the Company for the quarter and nine months ended December 31, 2022.
A copy of the Unaudited Financial Results for the quarter and nine months ended December 31, 2022 together with the limited review reports (standalone & consolidated) by the Statutory Auditors of the Company and Press Release along with presentation to the Investors/ Analysts, on the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 are enclosed herewith.
The above information will also be available on the website of the Company at www.neulandlabs.com.
The meeting of the Board of Directors of the Company commenced at 3:50 PM (1ST) and concluded at 5:30 PM (1ST).
This is for your information and records.
Thanking you,
Yours Sincerelyl
For Neuland Labof,at:���>'I d
Sara a arn1
Encl: As above
Registered Office: 11th Floor, (5th Office Level), Phoenix IVY Building, Plot No. 573A-III, Road No.82, Jubilee Hills, Hyderabad-500033, Telangana, India I CJN No. L85195TG1984PLC004393
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 13 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 February 2023 11:46:11 UTC.
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industryâs chemistry needs. The Company provide solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
NEULAND LABORATORIES LIMITED 
